|
1) Katsumoto K, Shiraki N, Miki R, et al. Embryonic and adult stem cell systems in mammals: ontology and regulation. Dev Growth Differ. 2010; 52: 115-29
|
|
|
|
2) Brittan M, Wright NA. Gastrointestinal stem cells. J Pathol. 2002; 197: 492-509
|
|
|
|
|
|
3) Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol. 2009; 217: 307-17
|
|
|
|
|
|
4) Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11: 1487-95
|
|
|
|
|
|
5) Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183: 1797-806
|
|
|
|
|
|
6) Kabashima A, Higuchi H, Takaishi H, et al. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer. 2009; 124: 2771-9
|
|
|
|
|
|
7) Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030-7
|
|
|
|
|
|
8) Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-23
|
|
|
|
|
|
9) Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010; 102: 340-51
|
|
|
|
|
|
10) Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004; 363: 1049-57
|
|
|
|
|
|
11) Scopelliti A, Cammareri P, Catalano V, et al. Therapeutic implications of Cancer Initiating Cells. Expert Opin Biol Ther. 2009; 9: 1005-16
|
|
|
|
|
|
12) Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets. 2009; 9: 354-65
|
|
|
|
|
|
13) Burkhart CA, Watt F, Murray J, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 2009; 69: 6573-80
|
|
|
|
|
|
14) Zhou J, Wang CY, Liu T, et al. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol. 2008; 14: 925-30
|
|
|
|
|
|
15) de Wolf C, Jansen R, Yamaguchi H, et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008; 7: 3092-102
|
|
|
|
|
|
16) Hong SP, Wen J, Bang S, et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009; 125: 2323-31
|
|
|
|
|
|
17) Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007; 14: 3629-37
|
|
|
|
|
|
18) Mfopou JK, De Groote V, Xu X, et al. Sonic hedgehog and other soluble factors from differentiating embryoid bodies inhibit pancreas development. Stem Cells. 2007; 25: 1156-65
|
|
|
|
|
|
19) Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425: 851-6
|
|
|
|
|
|
20) Strobel O, Rosow DE, Rakhlin EY, et al. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology. 2010; 138: 1166-77
|
|
|
|
|
|
21) Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell. 2005; 8: 185-95
|
|
|
|
|
|
22) Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009; 69: 2400-7
|
|
|
|
|
|
23) Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007; 104: 16158-63
|
|
|
|
|
|
24) Kayali AG, Van Gunst K, Campbell IL, et al. The stromal cell-derived factor-1alpha/CXCR4 ligand-receptor axis is critical for progenitor survival and migration in the pancreas. J Cell Biol. 2003; 163: 859-69
|
|
|
|
|
|
25) Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut. 2008; 57: 1420-30
|
|
|
|
|
|
26) Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 2006; 118: 2337-43
|
|
|
|
|
|
27) Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 2006; 5: 2676-84
|
|
|
|
|
|
28) Mueller MT, Hermann PC, Witthauer J, et al. Combined targeted treatment to eliminate tumori-genic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009; 137: 1102-13
|
|
|
|
|
|
29) Kallifatidis G, Rausch V, Baumann B, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut. 2009; 58: 949-63
|
|
|
|
|